Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Lymphoblastic Leukemia Undergoing Allo-HSCT
Status:
Recruiting
Trial end date:
2026-01-20
Target enrollment:
Participant gender:
Summary
The purpose of this prospective, open-label, single-center study is to evaluate the efficacy
and safety of VEN-AZA (venetoclax and azacytidine) followed by modified BUCY (busulfan and
cyclophosphamide) as conditioning regimen for high-risk or relapsed/refractory acute
lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation
(allo-HSCT).
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University